Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will have its leadership team, including CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal, participate in a virtual Fireside Chat at Citi's 2021 Healthcare Services conference on February 24 at 11:25 AM PST. This event highlights Bio-Rad's commitment to innovation in life science research and clinical diagnostics. With over 65 years of experience and revenues surpassing $2.5 billion in 2020, Bio-Rad continues to advance healthcare solutions globally.
Bio-Rad Laboratories reported Q4 2020 results with net sales of $789.8 million, a 26.5% increase from Q4 2019. Life Science segment sales surged 77.1% to $428.5 million, largely driven by COVID-19-related demand. Gross margin improved to 58.3% from 52.9% year-over-year. Net income soared to $839.1 million, or $27.81 per share, compared to $553.5 million, or $18.31 per share in Q4 2019. Clinical Diagnostics segment saw a 5.1% decrease in sales. The company was awarded Emergency Use Authorization for new COVID-19 tests.
Bio-Rad Laboratories will announce its financial results for Q4 and full year 2020 on February 11, 2021, post-market. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET) the same day. Investors can access the call by dialing 855-779-9068 within the U.S. or 631-485-4862 internationally, using Conference ID: 8269933. The call will also be available via a webcast on the company’s Investor Relations page, which will remain accessible for one year.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced participation in a virtual Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. The event will feature President and CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal. Investors can access the live webcast through the Investor Relations section on bio-rad.com. Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, with over $2.3 billion in revenue in 2019 and a workforce of more than 8,000 employees globally.
Bio-Rad Laboratories (NYSE: BIO) has announced its 2023 outlook, projecting sales between $2.75 billion and $2.85 billion. The forecast reflects the company's strong product portfolio, including Droplet Digital PCR and clinical diagnostics. Bio-Rad expects a non-GAAP adjusted EBITDA margin of 23-24%, aided by operating leverage and improvements in capacity utilization. CEO Norman Schwartz emphasized a focus on balancing innovation with operational discipline to support organic growth and sustainability efforts.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will announce its third-quarter 2020 financial results on October 29, 2020, after the market closes. A conference call is scheduled for 3 PM PT (6 PM ET) to discuss these results. The call can be accessed by dialing 855-779-9068 for U.S. callers or 631-485-4862 for international callers, using passcode 7061137. Additionally, interested parties can listen to the live webcast on the Investor Relations section of the company's website.